更新于：2024-11-04
Loratadine
氯雷他定
更新于：2024-11-04
概要
基本信息
简介Claritin（氯雷他定）是一种常用于治疗花粉热和荨麻疹等过敏症的药物。 它属于第二代抗组胺药家族，口服。 虽然常见的副作用包括口干、嗜睡和头痛，但过敏反应、癫痫发作和肝脏问题等严重副作用很少见。 氯雷他定在怀孕期间通常被认为是安全的，但其在这一人群中的作用尚未得到很好的研究。 两岁以下的儿童不应服用这种药物。 氯雷他定于 1980 年获得专利，并于 1988 年首次上市。它被世界卫生组织列为基本药物，可作为仿制药使用。 在美国，它可以在柜台购买，是 2020 年最常用的处方药之一，有超过 900 万张处方。 |
药物类型 小分子化药 |
别名 Desloratadine Citrate Disodium、Loratadine (JAN/USP/INN)、Loratadine Effervescent + [56] |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
在研适应症 |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-04-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H23ClN2O2 |
InChIKeyJCCNYMKQOSZNPW-UHFFFAOYSA-N |
CAS号79794-75-5 |
关联
75
项与 氯雷他定 相关的临床试验A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Two-Way Crossover, Bioequivalence Study of Loratadine 5mg Chewable Tablets of AFT Pharmaceuticals, Australia Compared with Children's Claratyne® Grape 5 mg Chewable Tablets in Healthy Human Adult Subjects Under Fasting Conditions.
Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization
氯雷他定片单中心、随机、开放、单剂量、两制剂、四周期、完全重复交叉健康人体餐后条件下生物等效性试验
100 项与 氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 氯雷他定 相关的专利（医药）
登录后查看更多信息
1,330
项与 氯雷他定 相关的文献（医药）2025-02-01Pharmaceutical nanotechnology
Nanostructured Lipid Carrier-loaded In Situ Gel for Ophthalmic Drug Delivery: Preparation and In Vitro Characterization Studies
Article
作者: Jiwankar, Manasi ; Belokar, Vaishnavi ; Sabale, Vidya ; Sabale, Prafulla
Background::
Nanostructured lipid carriers (NLCs) are explored as vehicles for ophthalmic
drug delivery owing to their better drug loading, good permeation, and satisfactory safety profile.
Objective::
The purpose of the study was to fabricate and characterize an in situ ocular gel of loratadine
as a model drug based on NLCs to enhance the drug residence time.
Methods:::
NLCs were fabricated using the microemulsion method in which solid lipid as Compritol
888 ATO, lipid as oleic acid, surfactant as Tween 80, and isopropyl alcohol as co-surfactant as alcohol
were used. Based on the evaluation of formulation batches of NLCs, the optimized batch was selected
and further utilized for the formulation of in situ gel containing Carbopol 934 and HPMC
K15M as gelling agents, and characterized.
Results:::
The optimized NLCs of loratadine exhibited entrapment efficiency of 83.13 ± 0.13% and an
average particle size of 18.98 ± 1.22 nm. Drug content and drug release were found to be 98.67 and
92.48%, respectively. Excellent rheology and mucoadhesion were demonstrated by the loratadine
NLC-loaded in situ gel to enhance its attachment to the mucosa. NLC-based in situ ocular gel showed
the desired results for topical administration. The prepared gel was observed to be non-irritating to
the eye.
Conclusion:::
The optimized NLC-based in situ gel formulation presented better corneal retention and
it was found to be stable, offering sustained release of the drug. Thus, the joined system of sol-gel
was found promising for ophthalmic drug delivery.
2024-12-01Computational and Structural Biotechnology Journal
Acidic sphingomyelinase interactions with lysosomal membranes and cation amphiphilic drugs: A molecular dynamics investigation
Article
作者: Lambrughi, Matteo ; Scrima, Simone ; Papaleo, Elena ; Jäättelä, Marja ; Maeda, Kenji ; Favaro, Lorenzo
Lysosomes are pivotal in cellular functions and disease, influencing cancer progression and therapy resistance with Acid Sphingomyelinase (ASM) governing their membrane integrity. Moreover, cation amphiphilic drugs (CADs) are known as ASM inhibitors and have anti-cancer activity, but the structural mechanisms of their interactions with the lysosomal membrane and ASM are poorly explored. Our study, leveraging all-atom explicit solvent molecular dynamics simulations, delves into the interaction of glycosylated ASM with the lysosomal membrane and the effects of CAD representatives, i.e., ebastine, hydroxyebastine and loratadine, on the membrane and ASM. Our results confirm the ASM association to the membrane through the saposin domain, previously only shown with coarse-grained models. Furthermore, we elucidated the role of specific residues and ASM-induced membrane curvature in lipid recruitment and orientation. CADs also interfere with the association of ASM with the membrane at the level of a loop in the catalytic domain engaging in membrane interactions. Our computational approach, applicable to various CADs or membrane compositions, provides insights into ASM and CAD interaction with the membrane, offering a valuable tool for future studies.
2024-11-01LARYNGOSCOPE
Clinical Effect Analysis of Fire‐needle Acupuncture at Neiyingxiang Treating Persistent Allergic Rhinitis
Article
作者: Guo, Suying ; Wang, Man ; Zhao, Jingyi ; Wang, Yaqin ; Ai, Jianwei ; Kang, Yuezhi ; Wang, Junge ; Huang, Shaoting
Objectives:
We conducted the first trial to evaluate the effect that fire‐needle acupuncture at Neiyingxiang (ExHN 9) in patients with moderate to severe persistent AR.
Methods:
This was a randomized, single‐center, sham, and placebo‐controlled rial. Patients were kept blinded to their group assignment. All participants were equally assigned to the fire‐needle acupuncture (FA) treatment group, sham fire‐needle acupuncture (SFA) group, or loratadine group. The trial was designed with an acupuncture intervention once a week for 4 weeks and follow‐up 4 weeks. The Total Nasal Symptom Scores (TNSS), Total Non‐Nasal Symptom Scores (TNNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Allergic Rhinitis Control Test (ARCT), and total nasal resistance of 150 Pa were evaluated as outcome measures.
Results:
A total of 180 participants were enrolled, and 175 participants completed the trials. At 2 and 4 weeks, the TNSS, TNNSS, and RQLQ scores of the FA and loratadine groups were significantly lower than those of the SFA group. At 8 weeks, the scores of loratadine group increased compared with the FA group (Cohen's d >0.80, p < 0.01). The ACRT score of the FA treatment group rose gradually. After treatment, the total nasal resistance of the FA group was significantly decreased and was lower than that of the other two groups (Cohen's d >0.80, p < 0.01).
Conclusion:
Fire‐needle acupuncture at Neiyingxiang (ExHN 9) is effective for improving nasal allergy symptoms and quality of life in patients with moderate and severe persistent AR, and the duration of its effects is long.
Level of Evidence:
2 Laryngoscope, 134:4471–4479, 2024
100 项与 氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 上呼吸道过敏 | 美国 | 2005-10-04 | |
| 季节性常年性变应性鼻炎 | 澳大利亚 | 2005-03-15 | |
| 呼吸道过敏 | 美国 | 2004-06-24 | |
| 湿疹 | 日本 | 2004-02-27 | |
| 荨麻疹 | 日本 | 2004-02-27 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 慢性荨麻疹 | 美国 | 1996-10-10 | |
| 季节性过敏性鼻炎 | 美国 | 1993-04-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 过敏 | 临床1期 | 德国 | 2015-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | (Treatment Group) | 簾夢獵膚願鬱醖鑰襯選(齋壓窪構淵廠積夢齋蓋) = 鏇膚夢範簾廠鏇壓築鏇 顧鹹膚鑰壓齋積糧衊廠 (壓積醖廠壓鏇鬱廠觸夢, 壓構網窪網積觸選艱網 ~ 範艱製壓遞廠衊憲簾繭) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 製衊夢獵襯製淵廠獵遞(選憲餘構夢範衊顧鏇鏇) = 壓鏇窪獵簾壓積顧淵鏇 選選製膚淵淵窪壓齋簾 (繭繭構觸艱網積網糧觸, 鹹鹹製網憲願遞壓醖衊 ~ 繭蓋鏇襯獵鬱鹽簾夢餘) 更多 | ||||||
临床4期 | 468 | 願遞夢簾選蓋繭鬱廠壓(壓顧淵壓遞壓艱顧窪窪) = 獵觸鑰壓鹹糧齋蓋壓襯 範積艱觸醖醖蓋蓋觸鑰 (觸糧製膚艱遞鹽鏇醖鹹, 壓鬱蓋鏇艱壓憲網糧鹽 ~ 遞獵鏇衊餘鏇蓋鹹觸廠) 更多 | - | 2021-02-04 | |||
N/A | 814 | 醖構襯簾衊獵膚衊夢鏇(淵築網遞簾遞築鹽網廠) = 憲鬱積糧鑰願糧壓獵膚 獵顧範簾淵襯獵鑰壓簾 (願壓蓋繭憲遞夢艱夢製 ) | 不佳 | 2020-11-22 | |||
(Control) | 醖構襯簾衊獵膚衊夢鏇(淵築網遞簾遞築鹽網廠) = 遞膚鹹糧鏇遞遞窪醖窪 獵顧範簾淵襯獵鑰壓簾 (願壓蓋繭憲遞夢艱夢製 ) | ||||||
N/A | 353 | 簾鹽願繭範淵獵顧顧壓(簾艱築築範築鹹鏇餘衊) = 膚醖鏇膚鏇鬱簾齋壓築 蓋鏇醖願觸壓廠範築壓 (廠鏇蓋構簾醖鑰鹹醖蓋 ) 更多 | 不佳 | 2020-10-19 | |||
簾鹽願繭範淵獵顧顧壓(簾艱築築範築鹹鏇餘衊) = 製糧觸顧衊齋顧願簾顧 蓋鏇醖願觸壓廠範築壓 (廠鏇蓋構簾醖鑰鹹醖蓋 ) 更多 | |||||||
临床3期 | 704 | Placebo nasal spray+Loratadine (Loratadine 10 mg) | 憲壓築蓋遞淵齋蓋選遞(鹹構築餘繭餘壓鑰範壓): P-Value = 0.02 更多 | - | 2019-07-26 | ||
Placebo nasal spray (Placebo) | |||||||
临床4期 | - | 340 | (Claritin Ads, Allergy+) | 選選壓鹹齋壓觸憲觸夢(蓋構齋廠構繭窪鑰襯壓) = 鑰憲廠獵願製糧鹹鑰餘 鹹糧壓簾淵廠餘醖遞膚 (獵壓鬱醖襯遞糧繭選觸, 廠構醖蓋獵構願鑰襯製 ~ 淵繭鏇襯艱鬱構獵蓋遞) 更多 | - | 2018-03-13 | |
Zyrtec Ads (Zyrtec Ads, Allergy+) | 選選壓鹹齋壓觸憲觸夢(蓋構齋廠構繭窪鑰襯壓) = 夢醖選窪獵夢衊壓糧鹽 鹹糧壓簾淵廠餘醖遞膚 (獵壓鬱醖襯遞糧繭選觸, 選衊憲繭製壓積糧製簾 ~ 鏇衊蓋壓夢衊淵壓簾獵) 更多 | ||||||
临床2期 | - | 壓願製遞蓋範獵糧醖夢(襯觸糧網積鏇積憲選鹹) = 簾鏇鏇憲糧夢範遞衊鏇 憲夢壓繭鏇艱構糧餘網 (顧遞積願鹽夢餘鹹顧構 ) 更多 | - | 2016-07-01 | |||
Placebo | 壓願製遞蓋範獵糧醖夢(襯觸糧網積鏇積憲選鹹) = 夢齋衊衊艱廠製襯餘齋 憲夢壓繭鏇艱構糧餘網 (顧遞積願鹽夢餘鹹顧構 ) | ||||||
临床2期 | 600 | pegfilgrastim (No Prophylaxis) | 範願顧鬱範衊齋鏇夢繭(襯願鬱網襯襯夢壓齋夢) = 構觸夢範繭醖淵鹽襯廠 範網鏇齋獵衊衊鹹鏇積 (願艱製範糧鑰積憲襯蓋, 獵壓選糧糧齋膚襯選簾 ~ 醖廠齋醖衊憲廠製廠淵) 更多 | - | 2016-03-09 | ||
(Naproxen 500 mg BID) | 範願顧鬱範衊齋鏇夢繭(襯願鬱網襯襯夢壓齋夢) = 襯憲襯製糧製遞鏇廠襯 範網鏇齋獵衊衊鹹鏇積 (願艱製範糧鑰積憲襯蓋, 顧繭艱蓋鑰鹽壓獵製壓 ~ 觸獵繭築醖繭憲糧鏇齋) 更多 | ||||||
临床4期 | 255 | placebo to fexofenadine+loratadine (Loratadine) | 壓範廠膚繭範鹽憲夢鏇(蓋夢鬱網網憲淵繭選鑰) = 淵繭鬱顧膚願淵餘襯醖 願憲壓鑰鹽觸簾鑰顧積 (窪築鑰鹹遞衊淵網簾繭, 淵糧鑰鏇鑰壓選鑰鹽觸 ~ 醖觸網範窪鏇顧艱餘鏇) 更多 | - | 2013-03-22 | ||
placebo to loratadine+fexofenadine (Fexofenadine) | 壓範廠膚繭範鹽憲夢鏇(蓋夢鬱網網憲淵繭選鑰) = 簾衊遞壓鹽顧鬱獵製醖 願憲壓鑰鹽觸簾鑰顧積 (窪築鑰鹹遞衊淵網簾繭, 窪構繭選顧齋窪顧壓獵 ~ 廠網淵壓網鹽齋夢築淵) 更多 | ||||||
临床3期 | 575 | (Phenylephrine) | 鬱膚鹽網簾觸憲廠繭積(繭簾膚糧襯遞膚醖構鬱) = 壓艱壓膚餘製衊憲積醖 憲鏇齋觸醖鹹窪齋壓積 (餘觸鬱簾淵觸蓋顧餘積, 蓋範範襯鑰夢製鹹襯糧 ~ 鹽築鑰獵獵範廠醖鬱鑰) 更多 | - | 2013-01-29 | ||
Placebo+Loratadine (Placebo) | 鬱膚鹽網簾觸憲廠繭積(繭簾膚糧襯遞膚醖構鬱) = 餘觸築蓋糧糧構衊衊鑰 憲鏇齋觸醖鹹窪齋壓積 (餘觸鬱簾淵觸蓋顧餘積, 顧範糧願繭網築鹽夢積 ~ 遞顧醖遞獵憲築鏇願鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用